People with chronic obstructive pulmonary disease (COPD) and arthritis have a higher risk of death than people with arthritis ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

In Japan, Novartis’ Ultibro and GlaxoSmithKline’s LAMA/LABA combination Anoro, are approved in COPD maintenance. Meanwhile in China older drugs such as salmeterol and formoterol are commonly ...

2-4 If approved, Nucala could be the first approved biologic with monthly dosing for patients with COPD. Nucala is currently approved for use in the China across three IL-5 mediated conditions.

People with chronic obstructive pulmonary disease (COPD) and arthritis have a higher risk of death than people with arthritis who do not have COPD ...

COPD, a progressive lung condition that affects over 390 million people worldwide, is particularly prevalent in China, where nearly 100 million individuals are living with the disease. This ...

The prevalence of fatigue among patients with chronic obstructive pulmonary disease (COPD) worldwide is approximately 59%, according to systematic review and meta-analysis findings published in ...

COPD, a progressive lung condition that affects over 390 million people worldwide, is particularly prevalent in China, where nearly 100 million individuals are living with the disease. This represents ...

People with chronic obstructive pulmonary disease (COPD) and arthritis have a higher risk of death than people with arthritis who do not have COPD, according to a new study.